Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis

Journal:

The New England Journal of Medicine

Published:

2026-05-19

DOI:

10.1056/nejmoa2501488

Affiliations:

19

Authors:

22

Go to article

Institutions	Authors	Share
United Therapeutics Corporation, United States of America (USA)	7.000000	0.32
Inova Fairfax Hospital, Inova Health System, United States of America (USA)	2.000000	0.09
Michigan Medicine, U-M, United States of America (USA)	1.000000	0.05
Medical University of South Carolina (MUSC), United States of America (USA)	1.000000	0.05
Centro Médico Dra. De Salvo, Argentina	1.000000	0.05
Lung Research Center, United States of America (USA)	1.000000	0.05
Tulane University, United States of America (USA)	1.000000	0.05
UCLA Health, United States of America (USA)	1.000000	0.05
OU Health Sciences Center (OUHSC), United States of America (USA)	1.000000	0.05
Firestone Institute for Respiratory Health (FIRH), Canada	1.000000	0.05
PulmonIx Research, LLC, United States of America (USA)	1.000000	0.05
University of Kansas Medical Center (KUMC), United States of America (USA)	1.000000	0.05
USF Health, United States of America (USA)	1.000000	0.05
University Hospital of Munich (KUM), LMU, Germany	0.333333	0.02
Infections Virales et Pathologie Comparée (IVPC), France	0.333333	0.02
Lyon University Hospital (HCL), France	0.333333	0.02
ERN LUNG, France, France	0.333333	0.02
The German Center for Lung Research (DZL), Germany	0.333333	0.02
Ludwig Maximilians University of Munich (LMU), Germany	0.333333	0.02

Interested in Cardiovascular Medicine and Haematology?